Do Patients Die with or from Metformin-Associated Lactic Acidosis (MALA)? Systematic Review and Meta-analysis of pH and Lactate as Predictors of Mortality in MALA.
Lactate
Lactic acidosis
Metformin
Mortality
Survival
Journal
Journal of medical toxicology : official journal of the American College of Medical Toxicology
ISSN: 1937-6995
Titre abrégé: J Med Toxicol
Pays: United States
ID NLM: 101284598
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
20
09
2019
accepted:
15
12
2019
revised:
04
12
2019
pubmed:
8
1
2020
medline:
1
6
2021
entrez:
8
1
2020
Statut:
ppublish
Résumé
Metformin-associated lactic acidosis (MALA) may occur after acute metformin overdose, or from therapeutic use in patients with renal compromise. The mortality is high, historically 50% and more recently 25%. In many disease states, lactate concentration is strongly associated with mortality. The aim of this systematic review and meta-analysis is to investigate the utility of pH and lactate concentration in predicting mortality in patients with MALA. We searched PubMed, EMBASE, and Web of Science from their inception to April 2019 for case reports, case series, prospective, and retrospective studies investigating mortality in patients with MALA. Cases and studies were reviewed by all authors and included if they reported data on pH, lactate, and outcome. Where necessary, authors of studies were contacted for patient-level data. Receiver operating characteristic (ROC) curves were generated for pH and lactate for predicting mortality in patients with MALA. Forty-four studies were included encompassing 170 cases of MALA with median age of 68.5 years old. Median pH and lactate were 7.02 mmol/L and 14.45 mmol/L, respectively. Overall mortality was 36.2% (95% CI 29.6-43.94). Neither lactate nor pH was a good predictor of mortality among patients with MALA. The area under the ROC curve for lactate and pH were 0.59 (0.51-0.68) and 0.43 (0.34-0.52), respectively. Our review found higher mortality from MALA than seen in recent studies. This may be due to variation in standard medical practice both geographically and across the study interval, sample size, misidentification of MALA for another disease process and vice versa, confounding by selection and reporting biases, and treatment intensity (e.g., hemodialysis) influenced by degree of pH and lactate derangement. The ROC curves showed poor predictive power of either lactate or pH for mortality in MALA. With the exception of patients with acute metformin overdose, patients with MALA usually have coexisting precipitating illnesses such as sepsis or renal failure, though lactate from MALA is generally higher than would be considered survivable for those disease states on their own. It is possible that mortality is more related to that coexisting illness than MALA itself, and many patients die with MALA rather than from MALA. Additional work looking solely at MALA in healthy patients with acute metformin overdose may show a closer relationship between lactate, pH, and mortality.
Identifiants
pubmed: 31907741
doi: 10.1007/s13181-019-00755-6
pii: 10.1007/s13181-019-00755-6
pmc: PMC7099117
doi:
Substances chimiques
Biomarkers
0
Hypoglycemic Agents
0
Lactic Acid
33X04XA5AT
Metformin
9100L32L2N
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
222-229Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
BMJ. 1993 Oct 23;307(6911):1056-7
pubmed: 8251784
Semin Dial. 2006 Jan-Feb;19(1):80-3
pubmed: 16423187
Indian J Crit Care Med. 2016 May;20(5):295-8
pubmed: 27275079
Int J Clin Pharmacol Ther. 2013 Feb;51(2):147-51
pubmed: 23149294
J Emerg Med. 2010 Jul;39(1):e77-80
pubmed: 18343080
J Clin Pharm Ther. 2011 Jun;36(3):376-82
pubmed: 21545617
Emerg Med J. 2002 Mar;19(2):169-71
pubmed: 11904273
Crit Care. 2010;14(6):R226
pubmed: 21171991
Cochrane Database Syst Rev. 2010 Apr 14;(4):CD002967
pubmed: 20393934
Presse Med. 1988 Jun 4;17(22):1158
pubmed: 2969545
G Ital Nefrol. 2018 Sep;35(5):
pubmed: 30234235
Br J Clin Pract. 1987 Mar;41(3):673-4
pubmed: 3689645
Case Rep Crit Care. 2018 May 8;2018:3868051
pubmed: 29854476
Diabetes Care. 1995 Jun;18(6):779-84
pubmed: 7555503
Crit Care Med. 2015 Aug;43(8):1716-30
pubmed: 25860205
Nouv Presse Med. 1976 Apr 10;5(15):1004
pubmed: 819905
Acta Biomed. 2009;80(3):262-4
pubmed: 20578420
Anesthesiology. 1997 Oct;87(4):1003-5
pubmed: 9357911
Eur J Clin Pharmacol. 1979 Jul;15(6):407-10
pubmed: 499289
Diabete Metab. 1980 Sep;6(3):199-203
pubmed: 6777210
Am J Med. 1997 May;102(5):486-8
pubmed: 9217647
Am J Nephrol. 1996;16(6):520-2
pubmed: 8955764
Diabetologia. 1974 Oct;10(5):485-7
pubmed: 4217736
Ann Emerg Med. 2009 Dec;54(6):818-23
pubmed: 19556031
J Med Case Rep. 2012 Aug 02;6:230
pubmed: 22857657
Diabetes Care. 1998 Aug;21(8):1364-5
pubmed: 9702449
J Emerg Med. 2011 Mar;40(3):271-5
pubmed: 18571361
N Z Med J. 1995 Jun 14;108(1001):230-1
pubmed: 7603655
Diabetes Res Clin Pract. 1997 Dec;38(3):173-6
pubmed: 9483383
Neth J Med. 2008 May;66(5):185-90
pubmed: 18490795
Sem Hop. 1981 Mar 18-25;57(11-12):586-7
pubmed: 6261339
Postgrad Med J. 1988 Mar;64(749):230-1
pubmed: 3174542
Neth J Med. 2003 Oct;61(10):331-3
pubmed: 14708912
Clin Sci (Lond). 2012 Mar;122(6):253-70
pubmed: 22117616
Eur J Emerg Med. 2009 Feb;16(1):11-3
pubmed: 18931616
Am J Med. 1996 Jul;101(1):109-10
pubmed: 8686704
PLoS One. 2011;6(8):e23200
pubmed: 21853087
Drug Saf. 1999 Apr;20(4):377-84
pubmed: 10230584
Medicine (Baltimore). 2016 Nov;95(46):e4998
pubmed: 27861334